

# Petra Zieglmayer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/206912/publications.pdf>

Version: 2024-02-01

46  
papers

1,549  
citations

304743

22  
h-index

302126

39  
g-index

46  
all docs

46  
docs citations

46  
times ranked

1668  
citing authors

#	ARTICLE	IF	CITATIONS
1	IgE recognition of the house dust mite allergen Der p 37 is associated with asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1031-1043.	2.9	19
2	IgE-reactivity patterns in Asian and central European cockroach sensitized patients reveal differences in primary sensitizing allergen sources. , 2022, , .		1
3	Clinical performance of house-dust-mite-specific subcutaneous immunotherapy in a postmarket noninterventional setting. <i>Allergo Journal International</i> , 2021, 30, 46-49.	2.0	2
4	Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1041-1052.	5.7	38
5	Burden of allergic rhinitis and impact of MP-AzeFlu from the patient perspective: pan European patient survey. <i>Current Medical Research and Opinion</i> , 2021, 37, 1259-1272.	1.9	3
6	Technical standards in allergen exposure chambers worldwide – an EAACI Task Force Report. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3589-3612.	5.7	23
7	Expression in <i>Escherichia coli</i> and Purification of Folded rDer p 20, the Arginine Kinase From <i>Dermatophagoides pteronyssinus</i> : A Possible Biomarker for Allergic Asthma. <i>Allergy, Asthma and Immunology Research</i> , 2021, 13, 154.	2.9	14
8	Allergen exposure chambers: implementation in clinical trials in allergen immunotherapy. <i>Clinical and Translational Allergy</i> , 2020, 10, 33.	3.2	12
9	Quantification, epitope mapping and genotype cross-reactivity of hepatitis B preS-specific antibodies in subjects vaccinated with different dosage regimens of BM32. <i>EBioMedicine</i> , 2020, 59, 102953.	6.1	10
10	Fast effectiveness of a solubilized low-dose budesonide nasal spray in allergic rhinitis. <i>Clinical and Experimental Allergy</i> , 2020, 50, 1065-1077.	2.9	5
11	A novel water-soluble budesonide nasal spray (Budesolv 10) improves asthmatic symptoms promptly in patients suffering from grass pollen allergic symptoms induced in an allergen exposure chamber. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, AB235.	2.9	0
12	The Role of Der p 23 Sensitization: An Analysis of 474 Patients Sensitized to Mite. <i>International Archives of Allergy and Immunology</i> , 2020, 181, 689-698.	2.1	6
13	Cetirizine inhibits gender-specific blood cell dynamics upon allergen contact in allergic rhinitis. <i>Clinical Immunology</i> , 2020, 215, 108422.	3.2	4
14	Vaccination of nonallergic individuals with recombinant hypoallergenic fragments of birch pollen allergen Bet v 1: Safety, effects, and mechanisms. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1258-1261.	2.9	29
15	Shortened up-dosing with sublingual immunotherapy drops containing tree allergens is well tolerated and elicits dose-dependent clinical effects during the first pollen season. <i>World Allergy Organization Journal</i> , 2019, 12, 100012.	3.5	3
16	P401 RAPID ONSET OF ACTION OF A NOVEL BUDESONIDE NASAL SPRAY IN GRASS POLLEN ALLERGIC RHINITIS. <i>Annals of Allergy, Asthma and Immunology</i> , 2019, 123, S57.	1.0	0
17	P451 SUPER- AND NON/LOW-RESPONDERS AMONG SUBJECTS WITH ALLERGIC RHINOCONJUNCTIVITIS RECEIVING HOUSE DUST MITE SUBLINGUAL IMMUNOTHERAPY TABLET. <i>Annals of Allergy, Asthma and Immunology</i> , 2019, 123, S58.	1.0	0
18	Perspectives in allergen immunotherapy: 2019 and beyond. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 3-25.	5.7	113

#	ARTICLE	IF	CITATIONS
19	Selection of house dust mite-specific allergic patients by molecular diagnosis may enhance success of specific immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1248-1252.e12.	2.9	56
20	Clinical reactivity of celery cultivars in allergic patients: Role of Api g 1. <i>Clinical and Experimental Allergy</i> , 2018, 48, 424-432.	2.9	8
21	Perspectives in allergen immunotherapy: 2017 and beyond. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 5-23.	5.7	76
22	Intranasal administration of allergen increases specific IgE whereas intranasal omalizumab does not increase serum IgE levels - A pilot study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1003-1012.	5.7	19
23	Underestimation of house dust mite-specific IgE with extract-based ImmunoCAPs compared with molecular ImmunoCAPs. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1656-1659.e9.	2.9	36
24	Clinical efficacy of sublingual immunotherapy is associated with restoration of steady-state serum lipocalin 2 after SLIT: a pilot study. <i>World Allergy Organization Journal</i> , 2018, 11, 21.	3.5	23
25	Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future - an EAACI Position Paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 1035-1042.	5.7	85
26	Clinical validation of a house dust mite environmental challenge chamber model. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 266-268.e5.	2.9	13
27	Possible effect of landscape design on IgE recognition profiles of two generations revealed with microarrayed allergens. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 1579-1582.	5.7	9
28	Sublingual house dust mite immunotherapy has no impact on decrease of circulating erythrocytes upon airway allergen challenge in allergic rhinitis. <i>Scientific Reports</i> , 2017, 7, 2555.	3.3	6
29	Molecular, Structural and Immunological Characterization of Der p 18, a Chitinase-Like House Dust Mite Allergen. <i>PLoS ONE</i> , 2016, 11, e0160641.	2.5	30
30	Long-term effects of a house dust mite sublingual immunotherapy tablet in an environmental exposure chamber trial. <i>Annals of Allergy, Asthma and Immunology</i> , 2016, 117, 690-696.e1.	1.0	25
31	Immunotherapy With the PreS-based Grass Pollen Allergy Vaccine BM32 Induces Antibody Responses Protecting Against Hepatitis B Infection. <i>EBioMedicine</i> , 2016, 11, 58-67.	6.1	45
32	Epitope specificity determines cross-protection of a SIT-induced IgG <sub>4</sub> antibody. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 36-46.	5.7	16
33	Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy. <i>EBioMedicine</i> , 2016, 11, 43-57.	6.1	109
34	Structural and Functional Characterization of the Major Allergen Amb a 11 from Short Ragweed Pollen. <i>Journal of Biological Chemistry</i> , 2016, 291, 13076-13087.	3.4	23
35	Randomized phase 1 study of the phosphatidylinositol 3-kinase $\gamma$ inhibitor idelalisib in patients with allergic rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1733-1741.	2.9	29
36	The improved efficacy of a fixed-dose combination of fluticasone furoate and levocabastine relative to the individual components in the treatment of allergic rhinitis. <i>Clinical and Experimental Allergy</i> , 2015, 45, 1346-1355.	2.9	17

#	ARTICLE	IF	CITATIONS
37	Effects of Nasal Corticosteroids on Boosts of Systemic Allergen-Specific IgE Production Induced by Nasal Allergen Exposure. PLoS ONE, 2015, 10, e0114991.	2.5	12
38	Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber. Journal of Allergy and Clinical Immunology, 2015, 135, 1494-1501.e6.	2.9	140
39	The effects of a TRPV1 antagonist, SB-705498, in the treatment of seasonal allergic rhinitis. International Journal of Clinical Pharmacology and Therapeutics, 2013, 51, 576-584.	0.6	34
40	The <sc>CRTH</sc>2 antagonist <sc>OC</sc>000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo-controlled, double-blind trial. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 1572-1579.	5.7	77
41	Intranasal Toll-like Receptor 8 Agonist (VTX-1463) Significantly Improves Symptoms of Allergic Rhinitis in a Randomized, Placebo-Controlled Trial. Journal of Allergy and Clinical Immunology, 2011, 127, AB199-AB199.	2.9	7
42	Changes in basophil activation during grass-pollen sublingual immunotherapy do not correlate with clinical efficacy. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 1530-1537.	5.7	50
43	The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflammation Research, 2010, 59, 391-398.	4.0	69
44	Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. Journal of Allergy and Clinical Immunology, 2009, 124, 471-477.e1.	2.9	174
45	A placebo-controlled study of the nasal decongestant effect of phenylephrine and pseudoephedrine in the Vienna Challenge Chamber. Annals of Allergy, Asthma and Immunology, 2009, 102, 116-120.	1.0	48
46	Fluticasone furoate versus placebo in symptoms of grass-pollen allergic rhinitis induced by exposure in the Vienna Challenge Chamber. Current Medical Research and Opinion, 2008, 24, 1833-1840.	1.9	31